GLPBio

Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Catalog No.: GC92134Purity:>95.00%Synonyms: Gastric Inhibitory Peptide; GIP
COASDSData Sheet
Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)は、グルコースに応答してインスリン分泌を誘導する内因性42アミノ酸ペプチドインクレチンホルモンです。

製品は研究用途にのみ使用できます。人体には使用できません。患者への販売は行っておりません。

Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)
1 mgIn Stock
$419.00
1
Tel: (909) 407-4943 / (909) 689-7124Email: sales@glpbio.com

引用文献 (Citations)

現在、この製品の引用文献はありません。以下はGlpBio製品を引用した代表的な文献です。
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

製品説明 (Description)

Glucose-dependent Insulinotropic Polypeptide (GIP) (human) is an endogenous 42-amino acid peptide incretin hormone that induces insulin secretion in response to glucose.1 It belongs to the secretin/glucagon superfamily of peptides, which includes secretin, glucagon, glucagon-like peptide-1 (GLP-1, GLP-2), and pituitary adenylate cyclase-activating polypeptide (PACAP).2 GIP is a GIP receptor agonist that binds to rat recombinant GIP receptors expressed in CHO-K1 cells (IC50 = 3.2 nM) and increases cAMP accumulation (EC50 = 377 pM).3 It stimulates insulin secretion from BRIN-BD11 rat pancreatic β-cells when used at a concentration of 10 nM.4 GIP (1 pmol/min per 100 g) decreases blood glucose level and increases plasma insulin level in rats following glucose challenge.3 It also decreases plasma glucose level and increases insulin level in ob/ob mice following glucose challenge when administered at a dose of 25 nmol/kg.5

References:
[1]. Baggio, L.L., and Drucker, D.J.Biology of incretins: GLP-1 and GIPGastroenterology132(6)2131-2157(2007).
[2]. Vaudry, D., Falluel-Morel, A., Bourgault, S., et al.Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discoveryPharmacol. Rev.61(3)283-357(2009).
[3]. Hinke, S.A., Manhart, S., Pamir, N., et al.Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP)Biochim. Biophys. Acta1547(1)143-155(2001).
[4]. Kerr, B.D., Flatt, A.J., Flatt, P.R., et al.Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptideBiochem. Biophys. Res. Commun.404(3)870-876(2011).
[5]. O'Harte, F.P., Hunter, K., Gault, V.A., et al.Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob miceAm. J. Physiol. Endocrinol. Metab.292(6)E1674-E1682(2007).

製品資料 (Product Documents)

Purity:>95.00%Appearance:A solid
COASDSData Sheet

化学的性質 (Chemical Properties)

同義語
Gastric Inhibitory Peptide; GIP
化学名
L-tyrosyl-L-alanyl-L-α-glutamylglycyl-L-threonyl-L-phenylalanyl-L-isoleucyl-L-seryl-L-α-aspartyl-L-tyrosyl-L-seryl-L-isoleucyl-L-alanyl-L-methionyl-L-α-aspartyl-L-lysyl-L-isoleucyl-L-histidyl-L-glutaminyl-L-glutaminyl-L-α-aspartyl-L-phenylalanyl-L-valyl-L-asparaginyl-L-tryptophyl-L-leucyl-L-leucyl-L-alanyl-L-glutaminyl-L-lysylglycyl-L-lysyl-L-lysyl-L-asparaginyl-L-α-aspartyl-L-tryptophyl-L-lysyl-L-histidyl-L-asparaginyl-L-isoleucyl-L-threonyl-L-glutamine, trifluoroacetate salt
SMILES
[H]N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(NCC(N[C@]([C@@H](C)O)([H])C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@@H](CO)C(N[C@H](C(N[C@H](C(N[C@@H](CO)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@H](C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@H](C(N[C@H](C(N[C@@H](CCCCN)C(N[C@H](C(N[C@@H](CC(N)=O)C(N[C@]([C@H](CC)C)([H])C(N[C@]([C@@H](C)O)([H])C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)CC1=CN=CN1)=O)=O)CC2=CNC3=C2C=CC=C3)=O)CC(O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)=O)=O)CC4=CNC5=C4C=CC=C5)=O)=O)=O)CC6=CC=CC=C6)=O)CC(O)=O)=O)=O)=O)CC7=CN=CN7)=O)=O)=O)CC(O)=O)=O)CCSC)=O)C)=O)=O)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)C)=O)CC%10=CC=C(O)C=C%10.FC(F)(C(O)=O)F
分子式
C226H338N60O66S ? XCF3COOH
分子量
4983.5
溶解性
Water: 1 mg/ml
保存条件
-20°C
一般的な注意事項
製品の溶解性データに基づいて適切な溶媒を選択してください。調製後は、凍結融解の繰り返しを避けるため、ストック溶液を小分けしてください。
ストック溶液は、-80°Cで保存する場合は6か月以内、-20°Cで保存する場合は1か月以内に使用してください。
溶解性を高めるには、チューブを37°Cに温め、適切な時間超音波処理してください。
配送条件
評価用サンプルは保冷剤とともに発送します。その他の容量は室温で発送し、ご要望に応じて保冷剤を同梱します。

計算ツール (Calculators)モル濃度 / 希釈 / 分子量 / 単位変換 / in vivo製剤 / 溶解度

g/mol

Reviews

Review for Glucose-dependent Insulinotropic Polypeptide (human) (trifluoroacetate salt)

Rating: 5
  • 5 Star100%
  • 4 Star0%
  • 3 Star0%
  • 2 Star0%
  • 1 Star0%